Individualized Approaches in 3L Treatment Selection for mRCC
An expert discusses how third line (3L) systemic therapy for metastatic renal cell carcinoma (mRCC) is guided by prior treatments, patient comorbidities, and drug-specific profiles. Options include tyrosine kinase inhibitors (TKIs; eg, tivozanib, cabozantinib), mTOR inhibitors (eg, everolimus), and immune-oncology– based approaches. Efficacy, tolerability (grade 3/4 adverse events [AEs]), and pharmacokinetic (PK) differences drive selection. Dose modifications, such as for tivozanib and lenvatinib/everolimus, balance efficacy and safety. Selection prioritizes sequencing strategy, with evidence (eg, Pal 2022) supporting reduced-dose efficacy.
Video content above is prompted by the following:
- Please discuss how you approach individualized 3L systemic therapy selection for patients with mRCC.
- Please offer perspectives on the pros/cons of current options for 3L therapy.
- What factors do you consider during treatment decision-making (eg, use of chemotherapy-sparing regimens, androgen receptor pathway inhibitor selection, triplet vs doublet combination systemic therapy)? For example:
- Efficacy
- Tolerability of each (eg, rate of grade 3/4 AEs)
- Patient clinical factors/comorbidities that would influence your use of each agent
- Are your 2L and 3L choices based on drug classification or on specific drugs?
- What are the similarities and differences between approved TKIs (eg, mechanism of action (MOA)/target selectivity, PK)?
- How do you handle dose modifications for tivozanib?
- What about for other options for mRCC (eg, lenvatinib/everolimus)?
- What are the data on the efficacy of these therapies with reduced dosages (eg, Pal 2022)?
Peers Discuss Management of IO/TKI Toxicities and Dosing Strategies in Frontline RCC
March 11th 2025During a Case-Based Roundtable® event, Elizabeth M. Wulff-Burchfield, MD, and other participants discussed their experiences with the frontline combination regimens for advanced renal cell carcinoma.
Read More
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
Beyond the First-Line: Economides on Advancing Therapies in RCC
February 1st 2024In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.
Listen
